EUVIMEDEUVIMED entdecken
Crossref

Fructosamine as a Complementary Biomarker to Hemoglobin A1c for Monitoring Glycemic Control in Diabetic Populations with Comorbidities

Anjani Kumar Chaturvedi, Shreya Nigoskar

IFR Journal of Medicine and Surgery · 10.10.2025 · 2 (4) · 9-16

DOI: 10.70146/msv02i04.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IFR Journal of Medicine and Surgery, erschienen am 10.10.2025. Verfasst von Anjani Kumar Chaturvedi und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes mellitus is a chronic metabolic disorder that requires effective glycemic control to prevent long-term complications. Hemoglobin A1c (HbA1c) is the most widely used biomarker for monitoring glycemic control; however, its accuracy is compromised in populations with comorbidities affecting red blood cell turnover, such as anemia, hemoglobinopathies, and chronic kidney disease (CKD). Fructosamine, a biomarker reflecting short-term glycemic control, offers a potential alternative to HbA1c.

Objective

This study aims to compare the effectiveness of HbA1c and fructosamine in assessing glycemic control, particularly in diabetic patients with anemia, hemoglobinopathies, and CKD, and to evaluate their predictive value for diabetes-related complications such as retinopathy, nephropathy, and neuropathy.

Methods

A prospective observational study was conducted involving 1,720 diabetic patients (860 in each HbA1c and fructosamine group). Participants were stratified into subgroups based on comorbid conditions, including anemia, hemoglobinopathies, and CKD. HbA1c and fructosamine were measured at baseline, three months, and six months. Sensitivity, specificity, and correlation analyses were performed to evaluate the biomarkers' predictive accuracy for complications.

Results

In the overall population, a significant positive correlation (r = 0.85, p < 0.001) was observed between HbA1c and fructosamine. However, the correlation was weaker in subgroups with anemia (r = 0.60), hemoglobinopathies (r = 0.58), and CKD (r = 0.62). Fructosamine demonstrated higher sensitivity and specificity for predicting diabetic nephropathy, retinopathy, and neuropathy, with a sensitivity of 92% for nephropathy compared to 85% for HbA1c (p < 0.05). In resource-limited settings, fructosamine was found to be a cost-effective alternative to HbA1c.

Conclusion

Fructosamine is a more reliable biomarker for assessing glycemic control in diabetic patients with anemia, hemoglobinopathies, and CKD, offering improved sensitivity for predicting diabetes-related complications. Its cost-effectiveness makes it a viable alternative to HbA1c, particularly in resource-limited settings.

Zitieren

APA

Chaturvedi, A. K., & Nigoskar, S. (2025). Fructosamine as a Complementary Biomarker to Hemoglobin A1c for Monitoring Glycemic Control in Diabetic Populations with Comorbidities. IFR Journal of Medicine and Surgery, 2(4), 9-16. https://doi.org/10.70146/msv02i04.002

Vancouver

Chaturvedi AK, Nigoskar S. Fructosamine as a Complementary Biomarker to Hemoglobin A1c for Monitoring Glycemic Control in Diabetic Populations with Comorbidities. IFR Journal of Medicine and Surgery. 2025;2(4):9-16. doi:10.70146/msv02i04.002

BibTeX
@article{Chaturvedi2025,
  author = {Chaturvedi, Anjani Kumar and Nigoskar, Shreya},
  title = {Fructosamine as a Complementary Biomarker to Hemoglobin A1c for Monitoring Glycemic Control in Diabetic Populations with Comorbidities},
  journal = {IFR Journal of Medicine and Surgery},
  year = {2025},
  volume = {2},
  number = {4},
  pages = {9--16},
  doi = {10.70146/msv02i04.002}
}
Kostenlos starten →